Melanoma cell galectin-1 ligands functionally correlate with malignant potential

Journal of Investigative Dermatology

Volumn 135, Issue 7, 2015, Pages 1849-1862

  Yazawa, Erika M ^a   Geddes Sweeney, Jenna E ^a   Cedeno Laurent, Filiberto ^a   Walley, Kempland C ^a   Barthel, Steven R ^a,b   Opperman, Matthew J ^a   Liang, Jennifer ^a   Lin, Jennifer Y ^a,b   Schatton, Tobias ^a,b   Laga, Alvaro C ^a,b   Mihm, Martin C ^a,b   Qureshi, Abrar A ^c   Widlund, Hans R ^a   Murphy, George F ^a,b   Dimitroff, Charles J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; GALECTIN 1; KIFUNENSINE; SIALYLTRANSFERASE; LIGAND; MCAM PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; CORRELATIONAL STUDY; DYSPLASTIC NEVUS; GENE EXPRESSION; GENE FUNCTION; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SKIN TUMOR; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD146; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GALECTIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MELANOMA; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84931026096     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.95     Document Type: Article

References (67)

1. Aisner DL, Maker A, Rosenberg SA, et al. (2005) Loss of S100 antigenicity in metastatic melanoma. Hum Pathol 36:1016-9
2. Andre S, Kojima S, Yamazaki N, et al. (1999) Galectins-1 and-3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposomebound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J Cancer Res Clin Oncol 125:461-74
3. Banh A, Zhang J, Cao H, et al. (2011) Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 71: 4423-31
4. Barthel SR, Antonopoulos A, Cedeno-Laurent F, et al. (2011) Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N-And O-glycans without direct incorporation. J Biol Chem 286: 21717-31
5. Baum LG, Seilhamer JJ, PangM, et al. (1995) Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj J 12:63-8
6. Blois SM, Ilarregui JM, Tometten M, et al. (2007) A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 13:1450-7
7. Braeuer RR, Shoshan E, Kamiya T, et al. (2012) The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res 25: 592-601
8. Camby I, Le Mercier M, Lefranc F, et al. (2006) Galectin-1: a small protein with major functions. Glycobiology 16:137R-157RR
9. Carlsson SR, Lycksell PO, Fukuda M (1993) Assignment of O-glycan attachment sites to the hinge-like regions of human lysosomal membrane glycoproteins lamp-1 and lamp-2. Arch Biochem Biophys 304: 65-73
10. Cedeno-Laurent F, Barthel SR, Opperman MJ, et al. (2010) Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol 185: 4659-72
11. Cedeno-Laurent F, Opperman M, Barthel SR, et al. (2012a) Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol 188:3127-37
12. Cedeno-Laurent F, Opperman MJ, Barthel SR, et al. (2012b) Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol 132:410-20
13. Cedeno-Laurent F, Watanabe R, Teague JE, et al. (2012c) Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119: 3534-8
14. Cho M, Cummings RD (1995) Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization. J Biol Chem 270:5198-206
15. Croci DO, Cerliani JP, Dalotto-Moreno T, et al. (2014) Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156:744-58
16. Croci DO, Salatino M, Rubinstein N, et al. (2012) Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 209:1985-2000
17. Demydenko D, Berest I (2009) Expression of galectin-1 in malignant tumors. Exp Oncol 31:74-9
18. Earl LA, Bi S, Baum LG (2010) N-And O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J Biol Chem 285:2232-44
19. Frank NY, Schatton T, Kim S, et al. (2011) VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 71: 1474-85
20. Fulcher JA, Chang MH, Wang S, et al. (2009) Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem 284:26860-70
21. Garin MI, Chu CC, Golshayan D, et al. (2007) Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109:2058-65
22. Hernandez JD, Nguyen JT, He J, et al. (2006) Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol 177: 5328-36
23. Iacobelli S, Arno E, D'Orazio A, et al. (1986) Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 46:3005-10
24. Ilarregui JM, Croci DO, Bianco GA, et al. (2009) Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10: 981-91
25. Inagaki Y, Sohma Y, Horie H, et al. (2000) Oxidized galectin-1 promotes axonal regeneration in peripheral nerves but does not possess lectin properties. Eur J Biochem 267:2955-64
26. Jean D, Gershenwald JE, Huang S, et al. (1998) Loss of AP-2 results in upregulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 273:16501-8
27. Jiang T, Zhuang J, Duan H, et al. (2012) CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 120:2330-9
28. Jouve N, Despoix N, Espeli M, et al. (2013) The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem 288:2571-9
29. Kaltner H, Lips KS, Reuter G, et al. (1997) Quantitation and histochemical localization of galectin-1 and galectin-1-reactive glycoconjugates in fetal development of bovine organs. Histol Histopathol 12:945-60
30. Kim HJ, Jeon HK, Cho YJ, et al. (2012) High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer 48:1914-21
31. Koopman LA, Kopcow HD, Rybalov B, et al. (2003) Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med 198:1201-12
32. Kopcow HD, Rosetti F, Leung Y, et al. (2008) T cell apoptosis at the maternalfetal interface in early human pregnancy, involvement of galectin-1. Proc Natl Acad Sci USA 105:18472-7
33. Laderach DJ, Gentilini LD, Giribaldi L, et al. (2013) A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 73:86-96
34. Lefranc F, Mathieu V, Kiss R (2011) Galectin-1 as an oncotarget in gliomas and melanomas. Oncotarget 2:892-3
35. Lehmann JM, Riethmuller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86:9891-5
36. Luca M, Hunt B, Bucana CD, et al. (1993) Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 3:35-41
37. Marcos NT, Pinho S, Grandela C, et al. (2004) Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-Associated sialyl-Tn antigen. Cancer Res 64:7050-7
38. Mathieu V, de Lassalle EM, Toelen J, et al. (2012) Galectin-1 in melanoma biology and related neo-Angiogenesis processes. J Invest Dermatol 132: 2245-54
39. Mills L, Tellez C, Huang S, et al. (2002) Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62:5106-14
40. Murugaesu N, Iravani M, van Weverwijk A, et al. (2014) An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov 4:304-17
41. Nguyen JT, Evans DP, Galvan M, et al. (2001) CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J Immunol 167:5697-707
42. Nishi N, Abe A, Iwaki J, et al. (2008) Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1. Glycobiology 18:1065-73
43. Ohannesian DW, Lotan D, Lotan R (1994) Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 54:5992-6000
44. Ouyang J, Juszczynski P, Rodig SJ, et al. (2011) Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 117:4315-22
45. Pace KE, Hahn HP, Pang M, et al. (2000) CD7 delivers a pro-Apoptotic signal during galectin-1-induced T cell death. J Immunol 165:2331-4
46. Perillo NL, Pace KE, Seilhamer JJ, et al. (1995) Apoptosis of T cells mediated by galectin-1. Nature 378:736-9
47. Plzak J, Smetana K Jr., Betka J, et al. (2000) Endogenous lectins (galectins-1 and-3) as probes to detect differentiation-dependent alterations in human squamous cell carcinomas of the oropharynx and larynx. Int J Mol Med 5: 369-72
48. Powell JT, Whitney PL (1984) Endogenous ligands of rat lung beta-galactoside-binding protein (galaptin) isolated by affinity chromatography on carboxyamidomethylated-galaptin-Sepharose. Biochem J 223: 769-74
49. Rabinovich GA, Iglesias MM, Modesti NM, et al. (1998) Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J Immunol 160: 4831-40
50. Rubinstein N, Alvarez M, Zwirner NW, et al. (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5:241-51
51. Skrincosky DM, Allen HJ, Bernacki RJ (1993) Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptinbinding glycoproteins. Cancer Res 53:2667-75
52. Stowell SR, Cho M, Feasley CL, et al. (2009) Ligand reduces galectin-1 sensitivity to oxidative inactivation by enhancing dimer formation. J Biol Chem 284: 4989-99
53. Suzuki O, Nozawa Y, Abe M (2005a) Altered N-glycosylation in CD45 and regulatory roles of altered N-glycosylation in galectin-1-induced growth inhibition in human diffuse large B cell lymphoma. Oncol Rep 13: 109-14
54. Suzuki O, Nozawa Y, Abe M (2005b) Regulatory roles of altered N-And O-glycosylation of CD45 in galectin-1-induced cell death in human diffuse large B cell lymphoma. Int J Oncol 26:1063-8
55. Szebeni GJ, Kriston-Pal E, Blazso P, et al. (2012) Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion. PLoS One 7:e41372
56. Thijssen VL, Barkan B, Shoji H, et al. (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70: 6216-24
57. Thijssen VL, Hulsmans S, Griffioen AW (2008) The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 172:545-53
58. Thijssen VL, Postel R, Brandwijk RJ, et al. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975-80
59. Tinari N, Kuwabara I, Huflejt ME, et al. (2001) Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 91:167-72
60. Toscano MA, Bianco GA, Ilarregui JM, et al. (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8:825-34
61. Tsai CM, Chiu YK, Hsu TL, et al. (2008) Galectin-1 promotes immunoglobulin production during plasma cell differentiation. J Immunol 181:4570-9
62. Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330:150-62
63. Woynarowska B, Dimitroff CJ, Sharma M, et al. (1996) Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue. Glycoconj J 13:663-74
64. Wu GJ, Fu P, Wang SW, et al. (2008) Enforced expression of MCAM/MUC18 increases in vitro motility and invasiveness and in vivo metastasis of two mouse melanoma K1735 sublines in a syngeneic mouse model. Mol Cancer Res 6:1666-77
65. Xie S, Luca M, Huang S, et al. (1997) Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57:2295-303
66. Zeng Q, Li W, Lu D, et al. (2012) CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 109:1127-32
67. Zuniga E, Rabinovich GA, Iglesias MM, et al. (2001) Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J Leukoc Biol 70:73-9